The international stem cell policy and ethics think tank, the Hinxton Group, weighed in yesterday on heritable human genetic modification with a new policy statement. The Hinxton statement is in many ways in agreement with the Baltimore, et al. Nature paper proposing a “prudent path forward” for human germline genetic modification, which came out of […]
Perspectives on Hinxton Human Germline Modification Statement Read More »
Professor Steven Pinker of Harvard has been making the case recently that when it comes to novel biotechnologies such as CRISPR-Cas9 that bioethics should just get out of the way. Further, he has argued that we do not need a moratorium on clinical use of CRISPR-Cas9 for human genetic modification. In fact, he says that
Why I Disagree with Steven Pinker On CRISPR Read More »
CRISPR-Cas9 gene editing technology is red-hot right now and I’ve been doing interviews with various thought leaders on it, which today includes Steven Pinker. This technology has great power for research in the lab and there are hypothetical transformative clinical applications of CRISPR too. The latter efforts could include experimental attempts at reversal of disease-causing
Steven Pinker interview: case against bioethocrats & CRISPR germline ban Read More »
Hank Greely over at The Center for Law and Biosciences at Stanford Law School was one of the participants in the recent Napa meeting on approaches to human germline genetic modification. Hank was also one of the authors on the resulting position paper in Science with David Baltimore as first author (here). Now Hank, pictured below,
Hank Greely Human Germline Modification Post Read More »
A new report from the National Academies of Sciences (NAS), Engineering, and Medicine here in the US recommends a policy significantly more cautious on first read for 3-person IVF than that in place now in the UK. My initial take on this new 164-page report is that it is very well thought out and the
NAS proposes prudent US policy on 3-person IVF Read More »